Sign in

NCT06710340Recruiting

Research on Effects of Acute Consumption of Nuts in Obese Diabetic Women

Influence of Acute Nut Intake on the Effects of High Saturated Fat Meals in Obese Diabetic Women

Source: ClinicalTrials.gov · Last updated 6 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Obesity is a multifactorial disease in which excess body fat accumulation increases the risk of other chronic diseases such as type 2 diabetes. The primary cause of obesity is the energy imbalance between calories consumed and expended. A balanced diet is essential for weight control and maintaining a healthy body weight. In this context, the intake of a high saturated fat meal (HSFM) plays a detrimental role, contributing to the development of obesity, type 2 diabetes, cancer, cardiovascular diseases, and exacerbating chronic inflammation. Additionally, it may induce metabolic endotoxemia and modulate profiles of circulating microRNAs. Therefore, due to the harmful health impacts of HSFM, studies on metabolomics and circulating microRNA levels could enhance understanding of the mechanisms of walnuts (Juglans regia) in the prevention and treatment of diseases. The aim of this study is to evaluate whether acute walnut supplementation attenuates the inflammatory response, oxidative stress, glycemic response, and regulates the metabolomic and circulating microRNA responses induced by HSFM in women with obesity and type 2 diabetes. The study will be randomized and crossover, including obese, non-insulin-dependent diabetic women aged over 18, without other comorbidities. In the first phase, participants will arrive at the clinic after a 10-hour fast and will be offered HSFM with or without 30g of walnuts. In the second phase, participants who did not receive walnuts will now receive them along with the HSFM and vice versa. Blood samples will be collected, and serum insulin, glucose, serum biomarkers of inflammation and oxidative stress will be evaluated. TNF-alpha, IL-6, IL-1β, IL-1ra, IL-8, and IL-10 will be measured by ELISA, and MDA by HPLC. Additionally, metabolomic and microRNA analyses will be conducted. Data analysis will be performed using JAMOVI v 2.3.21, with a significance level of 5%.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
15 (estimated)
First submitted
12 Nov 2024
Start date
15 Jan 2025
Primary completion date
15 Apr 2025
Lead sponsor
Raquel Ballarin
NCT number
NCT06710340

What you commit to

  • Study type: Interventional
  • Planned participants: 15
  • From 15 Jan 2025 to the primary completion date, 15 Apr 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of dietary supplements or corticosteroid use in the last 3 months

Other illness

  • Diagnosis of insulin dependent diabetes
  • Diagnosis of cancer
  • Diagnosis of heart failure
  • Diagnosis of kidney diseases
  • Diagnosis of liver diseases
  • Diagnosis of lung diseases
  • Diagnosis ofneurological diseases
  • Diagnosis of allergy to any component of the high saturated fat meal or walnuts

Who the study is looking for

  • Women over 18 years of age
  • Diagnosis of obesity (body mass index \[BMI \>30 kg/m²\])
  • Diagnosis of non-insulin-dependent type II diabetes

Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
São Paulo State University (UNESP), Medical School, Botucatu
Coordinator of this site? Confirm its status
BotucatuBrazilRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.